Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
TALAPRO-1 trial: what clinicians have said so far
A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer
- NCT03148795 ↗
- Completed
- Pfizer
- Standard size, estimated: 151–300 verified statements once built
We haven't built an HCP commentary report on TALAPRO-1 (talazoparib in metastatic castration-resistant prostate cancer with DNA repair alterations) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TALAPRO-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 9 posts on X, typically up to 40 once built | |
| 6 YouTube videos, typically up to 26 once built | |
| 6 podcast episodes, typically up to 26 once built |
The trial
ClinicalTrials.gov- Official title
- TALAPRO-1: A PHASE 2, OPEN-LABEL, RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANE-BASED CHEMOTHERAPY AND PROGRESSED ON AT LEAST 1 NOVEL HORMONAL AGENT (ENZALUTAMIDE AND/OR ABIRATERONE ACETATE/PREDNISONE)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Prostate Cancer
- Interventions
- Talazoparib
- Arms
- Talazoparib · Experimental
- Enrollment
- 128
- Primary outcomes
- Best Objective Response Rate (ORR)
- Sponsor
- Pfizer with Medivation, Inc.
- Start
- Jul 4, 2017
- Primary completion
- Sep 4, 2020
- Results posted
- Yes
- Registry record
- NCT03148795 · updated Apr 5, 2024
Publications
linked from the registry- Castro E, Douglas Laird A, Mehra N, Dorff T, Zhao S, van Oort I, Gasparro D, Calabro F, Pignata S, Geczi L, Barthelemy P, Kilari D, Graf RP, Chen HC, Healy CG, Scagliotti GV, Chelliserry J, Kennedy D, Fizazi K, de Bono JS. Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer. Eur J Cancer. 2026 Sep 29;248:117079. doi: 10.1016/j.ejca.2026.117079. Online ahead of print. PubMed 42849324
- Mehra N, Fizazi K, de Bono JS, Barthelemy P, Dorff T, Stirling A, Machiels JP, Bimbatti D, Kilari D, Dumez H, Buttigliero C, van Oort IM, Castro E, Chen HC, Di Santo N, DeAnnuntis L, Healy CG, Scagliotti GV. Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. Oncologist. 2022 Oct 1;27(10):e783-e795. doi: 10.1093/oncolo/oyac172. PubMed 36124924
- de Bono JS, Mehra N, Scagliotti GV, Castro E, Dorff T, Stirling A, Stenzl A, Fleming MT, Higano CS, Saad F, Buttigliero C, van Oort IM, Laird AD, Mata M, Chen HC, Healy CG, Czibere A, Fizazi K. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet Oncol. 2021 Sep;22(9):1250-1264. doi: 10.1016/S1470-2045(21)00376-4. Epub 2021 Aug 10. PubMed 34388386